左氧氟沙星治疗耐多药肺结核的效果与安全性

Abstract
Figure/Table
References (16)
Related Citation (15)

Download: PDF (0 KB) HTML (31 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To analyze the effect and safety of Levofloxacin in the treatment of multidrug-resistant pulmonary tuberculosis.Methods Eighty patients withmultidrug-resistant pulmonary tuberculosiswho were treated in our hospital from January 2018 to January 2019 were selected as the research objects,and they were divided into the control group(n=40)and the observation group(n=40)by the random listmethod.Patients in the control group received conventional drug treatment,and patients in the observation group received Levofloxacin treatment on the basis of the control group.The therapeutic effect,levels of inflammatory factors(tumor necrosis factor-α [TNF-α],interleukin-6[IL-6],interleukin-1 [IL-1])before and after treatment and the total incidence rate of adverse reactions were observed in the two groups.Results The total effective rate of treatment in the observation group was 97.50%,which was higher than that in the control group accounting for 82.50%,and the difference was statistically significant(P＜0.05).The levels of TNF-α,IL-6 and IL-1 after treatment in the two groups were lower than those before treatment,and the differences were statistically significant(P＜0.05).The levels of TNF-α,IL-6 and IL-1 after treatment in the observation group were lower than those in the control group,and the differences were statistically significant(P＜0.05).During the drug treatment period,the total incidence rate of adverse reactions in the observation group was 15.00%,compared with 12.50%in the control group,and the difference was not statistically significant(P＞0.05).Conclusion Levofloxacin in the treatment of patients withmultidrug-resistant pulmonary tuberculosis can significantly reduce the level of inflammatory factors and improve the therapeutic effect.At the same time,patients have fewer adverse reactions and have higher safety,which is worthy of being promoted and applied.

Key words： Multidrug-resistant pulmonary tuberculosis Levofloxacin Therapeutic effect Adverse reactions Inflammatory factors

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WU Cheng-bo

Cite this article:

WU Cheng-bo. Effect and safety of Levofloxacin in the treatment of multidrug-resistant pulmonary tuberculosis[J]. 中国当代医药, 2020, 27(9): 44-46.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2020/V27/I9/44

[1]	刘幸，欧阳兵，杜映荣，等.内消瘰疬丸联合左氧氟沙星治疗耐多药肺结核的临床疗效分析[J].中国医药导刊，2017，19（8）：787-790.
[2]	夏衣扎提·库尔曼，古丽巴哈尔·阿不拉合买提.耐多药结核病不同诊疗方案的疗效观察[J].中国社区医师，2017，33（7）：22-23.
[3]	赵忠勤.左氧氟沙星联合抗结核化疗方案治疗复治涂阳肺结核的临床研究[J].中国冶金工业医学杂志，2018，35（5）：561-562.
[4]	唐瑶.奈替米星+左氧氟沙星对耐多药肺结核治疗效果及对痰菌转阴率影响评价[J].临床检验杂志（电子版），2018，7（4）：714-715.
[5]	刘智，傅佳鹏，杨梁梓，等.左氧氟沙星和莫西沙星治疗耐多药肺结核临床疗效比较[J].临床肺科杂志，2017，22（4）：711-714.
[6]	张宗华，季乐财，邓伟忠.含左氧氟沙星或莫西沙星方案治疗耐多药肺结核临床疗效与安全性研究[J].中国药业，2017，26（4）：59-61.
[7]	陈廷宪，莫思柏.左氧氟沙星联合卷曲霉素治疗耐多药肺结核患者对免疫功能的改善效果[J].临床医学，2017，37（2）：12-14.
[8]	黄爱国.联合应用莫西沙星或左氧氟沙星治疗耐多药肺结核疗效分析[J].中国现代药物应用，2017，11（15）：116-117.
[9]	伏志杰.莫西沙星及左氧氟沙星对耐多药肺结核病的临床安全性评价[J].实用中西医结合临床，2017，17（7）：61-62.
[10]	朱杰.使用莫西沙星与左氧氟沙星辅助治疗耐多药肺结核的临床效果对比[J].当代医药论丛，2018，16（12）：153-155.
[11]	张琳，康健，鲜小萍.115例复治涂阳肺结核患者耐药状况及耐药原因分析[J].中国防痨杂志，2018，40（3）：292-295.
[12]	郝凤娟.左氧氟沙星治疗耐多药肺结核的临床效果和不良反应体会[J].临床医药文献电子杂志，2018，5（68）：152-153.
[13]	晏伟，顾玉兰.左氧氟沙星治疗耐多药肺结核的临床有效性评析[J].临床医药文献电子杂志，2018，5（23）：35.
[14]	刘丽君.左氧氟沙星治疗耐多药肺结核的价值和不良反应评价[J].中西医结合心血管病电子杂志，2019，7（3）：189.
[15]	赵华，徐萌，段宏章，等.探讨左氧氟沙星和卷曲霉素联合化疗方案用于耐多药肺结核的临床效果[J].中国卫生标准管理，2017，8（24）：82-84.
[16]	邵妍.左氧氟沙星联合卷曲霉素化疗在耐多药肺结核治疗中的应用价值分析[J].中国现代医生，2017，55（1）：71-73，76.